суббота, 4 февраля 2012 г.

Missouri's Constitutional Amendment Protecting Stem Cell Research Encounters 'Political, Financial Roadblocks,' New York Times Reports

A constitutional amendment approved by Missouri voters in November 2006 that was expected to expand and protect human embryonic stem cell research in the state has "run into political and financial roadblocks, putting the future of the research in doubt," the New York Times reports. According to the Times, the debate over the amendment has become a "fight over what constitutes 'cloning.'"

Supporters of the amendment say that it bans human cloning, which is defined in the amendment as an act that could result in a pregnancy and the creation of a human fetus inside a woman's uterus. Opponents say that cloning is the replication of cells, regardless of implantation in the uterus. Some state lawmakers who oppose the amendment said they will continue to fight it by introducing new bills that would ban some types of stem cell research.

"We think it's a false distinction to say that a clone exists only based on geography," Pam Fichter, president of Missouri Right to Life, said, adding that the group supports "ethical stem cell research, and we think cloning was misrepresented to voters. We know that a majority of Missourians oppose cloning." Donn Rubin -- chair of the Missouri Coalition for Lifesaving Cures, which led efforts to pass the amendment -- said that reproductive cloning was a major concern among voters. "What we protect is a very promising form of medical research that involves cells in a lab dish, not something that involves pregnancy," Rubin said.

Jaci Winship, executive director of Missourians Against Human Cloning, said the group is considering the possibility of a new initiative against the amendment, perhaps as soon as next year. Members of MRTL have been gathering signatures and contributions for the effort, the Times reports. According to Rubin, MCLC has continued raising money to prepare for another fight over the amendment.

Future of Research
According to the Times, although legislative efforts have failed so far, the "uncertainty" of the research's future in the state has made it difficult for facilities to attract stem cell specialists (Davey, New York Times, 8/10).

Many scientists who considered moving to Missouri to conduct stem cell research will not come to the state because of the uncertainty over whether the legislation will be overturned. The Stowers Institute for Medical Research in late July canceled plans to expand in Kansas City, Mo., because it was unable to recruit top stem cell researchers. The institute also transferred a large portion of its $2 million endowment to Delaware because the political climate in Missouri was too hostile (Kaiser Daily Women's Health Policy Report, 8/1).














Kevin Eggan, an assistant professor of molecular and cellular biology at Harvard University, said he strongly considered moving to Stowers but delayed his plans. "Everybody hoped that Missouri was going to be a good test case," Eggan said, adding, "It was exciting to us that stem cell research was being voted in a state which has very restrictive abortion laws. But it has turned out to be a big disappointment."

Sen. Chuck Graham (D) said, "For a bright shining moment in time, we were moving ahead as a state to protect research." He added, "But now the other side wants to walk away, not only from stem cell research, but all research. Their attitude now is, if there's a beaker or a Petri dish involved, we're not going to fund it." Rep. Jim Lembke (R), who opposes embryonic stem cell research and proposed legislation outlawing elements of the research, said, "As people are educated about this issue, they come around" (New York Times, 8/10).

"Reprinted with permission from kaisernetwork. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at kaisernetwork/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

суббота, 28 января 2012 г.

European Guidance For Osteoporosis Diagnosis And Management

The International Osteoporosis Foundation (IOF) has welcomed the recently published paper European guidance for the diagnosis and management of osteoporosis in postmenopausal women(1) from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).



This paper constitutes a roadmap for European countries to practically implement the new FRAX™ tool based on the WHO technical report, Assessment of osteoporosis at the primary health care level(2,3). The European guidance, published in Osteoporosis International, is a critical review of diagnostic methods, treatments and their monitoring options. It also shows case-finding strategies supported by health economic data.



IOF sees the ESCEO guidance as a positive move towards using the FRAX™ algorithm in daily practice. The WHO report and FRAX™ tool, released on February 21, 2008, help health practitioners to better understand the new paradigm for diagnosis and management of people at risk of developing fragility fractures.



In this regard, there will be a FRAX™ exhibition booth at the forthcoming ECCEO 8 Congress in Istanbul, Turkey, to be held at the Grand Cevahir Hotel & Convention Center. Participants will have the opportunity to have their 10-year fracture risk calculated, based on their geographic origin and individual risk factors. As a next step, the ESCEO paper can contribute with guidance on how to manage or monitor their condition, in the most rationale and cost-effective way.



Professor Jean-Yves Reginster, President of ESCEO, noted, "The ESCEO European guidance is convergent with the WHO report on how to assess and treat postmenopausal women with or at risk from osteoporosis. Moreover, cost-effectiveness analyses which illustrate scenarios based on a UK setting provide a starting point for health policy makers and health care providers to develop national guidelines on diagnosis and intervention thresholds."



The ESCEO guidance is very timely, as across Europe, osteoporosis is a major public health problem with serious medical and economic impact. In 2000, throughout the region, there were an estimated 620,000 new hip fractures, 574,000 forearm fractures, 250,000 shoulder fractures, and 620,000 spinal fractures in men and women aged 50 years or over, accounting for 34.8% of such fractures worldwide(4). There are more than 2.7 million osteoporotic fractures in men and women in Europe at a direct cost of 36 billion euros(5). It is estimated that by 2050, direct costs related to hip fractures will increase to 76.7 billion euros(6).







Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster, JY, Borgstr?¶m F, Rizzoli R, on behalf of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008 Feb 12; [Epub ahead of print]
















Kanis JA on behalf of the World Health Organization Scientific Group (2008) Assessment of osteoporosis at the primary health care level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases. University of Sheffield, UK.



World Health Organization. Assessment of osteoporosis at the primary health care level. Summary Report of a WHO Scientific Group. WHO, Geneva. who.int/chp/topics/rheumatic/en/index.html



Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726-1733



Kanis JA, Johnell O, on behalf of the Committee of Scientific Advisors of the International Osteoporosis Foundation (2005) Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 16:220-238



Kanis JA et al. Requirements for DXA for the management of Osteoporosis in Europe. Osteoporosis Int. 2005;16:229-38)



Osteoporosis, in which the bones become porous and break easily, is one of the world's most common and debilitating diseases. The result: pain, loss of movement, inability to perform daily chores, and in many cases, death. One out of three women over 50 will experience osteoporotic fractures, as will one out of five men (7,8,9).



Unfortunately, screening for people at risk is far from being a standard practice. Osteoporosis can, to a certain extent, be prevented, it can be easily diagnosed and effective treatments are available.



The International Osteoporosis Foundation (IOF) is the only worldwide organization dedicated to the fight against osteoporosis. It brings together scientists, physicians, patient societies and corporate partners.



Working with its 184 member societies in 89 locations, and other healthcare-related organizations around the world, IOF encourages awareness and prevention, early detection and improved treatment of osteoporosis.



Melton U, Chrischilles EA, Cooper C et al. How many women have osteoporosis" Journal of Bone Mineral Research, 1992; 7:1005-10



Kanis JA et al. Long-term risk of osteoporotic fracture in Malmo. Osteoporosis International, 2000; 11:669-674



Melton LJ, et al. Bone density and fracture risk in men. JBMR. 1998; 13:No 12:1915



For more information on osteoporosis and IOF please visit: iofbonehealth/



Source: janice blondeau


International Osteoporosis Foundation

суббота, 21 января 2012 г.

Bionovo Completes Enrollment Of MF101 Phase 2 Trial To Evaluate A Safer, New Therapy For Menopausal Symptoms

Bionovo, Inc.
(OTC Bulletin Board: BNVI) provided an update on its Phase 2 clinical trial
of MF101, a novel, oral treatment for hot flashes and other symptoms of
menopause. The Company has fully enrolled its FDA-approved trial with 184
women volunteers. Dr. Deborah Grady at the University of California, San
Francisco is serving as the Principal Investigator and the multi-center
trial is being conducted at six clinical sites across the country. The
trial will evaluate the efficacy of MF101 on actual and perceived relief
from menopausal symptoms. The women enrolled in the trial are aged 40-60
and experiencing greater than 7 moderate-to-severe hot flashes each day.



MF101 is an estrogen receptor beta (ER-beta) selective drug developed
as an alternative to those products currently on the market that have been
shown to increase the risk for breast and uterine cancers. Bionovo
recognized the opportunity to commercialize a product that would be equally
effective, with an improved safety profile to hormone therapy, and began
the clinical development of MF101. The drug candidate has been evaluated by
an independent Data and Safety Monitoring Board and has passed through a
standard two-round examination for safety. The Phase 2 study is expected to
run for an additional four months with results anticipated in early April
2007.



"For too long women had to face the choice between quality of life and
their long-term health," said Isaac Cohen, President and CEO, Bionovo. "The
market for menopausal products is enormous and growing, and we believe
there is great opportunity for a product that offers both efficacy and
safety."



The Phase 2 trial is a double-blind, randomized, placebo-controlled
trial. Women volunteers were randomized to groups of 60 receiving 2 doses
of MF101 or placebo. The trial is being conducted at the following sites:
University of California, San Francisco, University of Pittsburgh,
University of Minnesota, University of Tennessee, University of Alabama and
the San Diego Medical Center for Clinical Research.



About MF101



MF101, an ER-beta selective agonist, is designed for the treatment of
vasomotor symptoms such as hot flashes and night sweats in postmenopausal
women. In animal studies, MF101 has been shown to prevent tumor formation
in the breast and uterus, suggesting that Bionovo's lead drug will not
increase the risk of either breast or uterine cancer. In Phase 1 clinical
testing of MF101, the drug was found to be safe, well tolerated and taken
with high compliance. A multi-center, Phase 2, double-blind,
placebo-controlled, randomized clinical trial of MF101 has completed full
enrollment of 180 patients.



About Bionovo, Inc.



Bionovo is a drug development company focusing on the discovery of
novel pharmaceutical agents for cancer and women's health. The company has
one drug in Phase 2 clinical testing to treat conditions associated with
menopause and a second drug, BZL101, for breast cancer that will enter
Phase 2 clinical testing later this year. The company is developing its
products in close collaboration with leading U.S. academic research
centers, including the University of California, San Francisco, University
of Colorado Health Sciences Center, University of California, Berkeley, and
the University of Texas, Southwestern. For further information please
visit: bionovo/.


Bionovo, Inc

bionovo/

суббота, 14 января 2012 г.

How Predictable Are Urinary Tract Infections?

It is expected that women will experience urinary tract infections (UTIs) at least twice during their lifetime. If a test existed that could predict UTIs, health care providers and patients would benefit. In the February 2008 issue of Urologic Nursing, Deborah Kuklinski and Sumana Koduri explore using urine dipsticks, an in-office test, to predict UTI.


Kuklinski and Koduri say a urine dipstick positive for nitrites (produced by bacteria in a UTI) implies UTI, but the urine culture, which takes longer and is more expensive, is the gold standard for a positive diagnosis. If the urine dipstick could be used to diagnose a UTI, say the authors, treatment could begin immediately. They found that despite associating urine dipsticks and urine cultures positive for nitrites, 40%-50% of the UTIs would have been missed without the urine culture due to the sensitivity of the bacteria.


Although Kuklinski and Koduri couldn't conclude the urine dipstick accurately diagnosed UTI, their study indicates the urine culture is still important for diagnosis and treatment. They recommend practitioners continue to use the urine culture and offer patient education on UTI symptoms.


Predicting Urinary Tract Infections in a Urogynecology Population

Deborah Kuklinski, MS, RNC, WHNP; Sumana Koduri, MD

Urologic Nursing; February 2008

suna


The Society of Urologic Nurses and Associates is a national, non-profit professional membership association with over 3,000 members and annual revenues of $1.5 million. SUNA derives its income from membership dues (only $60), conference registration fees, exhibits, advertising, grants, and the sale of educational products.


SUNA publishes a professional, peer-reviewed bi-monthly journal (Urologic Nursing Journal) and a bi-monthly newsletter (Uro-Gram). SUNA establishes the scope and standards of urologic nursing practice and the scope and standards of advanced urologic nursing practice. SUNA provides scholarships, grants and awards to deserving nurses and other health care professionals.


SUNA supports and promotes the certification of urologic nurses and associates by providing educational preparation for the examinations offered which lead to certification in three areas.


SUNA provides a variety of opportunities for participation including local chapters, task forces and Special Interest Groups (SIGS) in five major subspecialty areas.


suna

суббота, 7 января 2012 г.

Family Lifespan Boosted By Late Motherhood

Women who have babies naturally in their 40s or 50s tend to live longer than other women. Now, a new study shows their brothers also live longer, but the brothers' wives do not, suggesting the same genes prolong lifespan and female fertility, and may be more important than social and environmental factors.



"If women in your family give birth at older ages, you may well have a chance of living longer than you would otherwise," says the study's lead author, demographer Ken R. Smith, a professor of family and consumer studies at the University of Utah. "If you have a female relative who had children after age 45, then there may be some genetic benefit in your family that will enhance your longevity."



For descendants of the Utah and Quebec pioneers studied, "you may be able to look at the ages when your female ancestors gave birth - rather than just their longevity - in estimating how long you may live," says Smith, whose study will be published online May 4 and in the June 10 print issue of the Journal of Gerontology: Biological Sciences.



The researchers examined high-quality genealogical records from the Utah Population Database at the University of Utah with its records of 1.6 million Utah Mormon pioneers and their descendants. They also used the University of Montreal's Program on Demographic History Research, which has records on 400,000 people who lived in heavily Catholic Quebec between 1608 and 1850.



Specifically, the study involved the records of 11,604 Utah men who were born between 1800 and 1869 and who had at least one sister who lived at least to age 50; and the records of 6,206 Quebec men who lived between 1670 and 1750, and had at least one sister who lived to 50 or older. The key findings:
Women who had "late fertility" - a birth at age 45 or older - were 14 percent to 17 percent less likely to die during any year after age 50 than women who did not deliver a child after age 40. That confirmed earlier studies. But those studies did not determine if the women gave birth later and lived longer because of genes or because of social and environmental factors such as good nutrition or healthy living.


Brothers who had at least three sisters, including at least one sister who gave birth at age 45 or later, were 20 percent to 22 percent less likely to die during any year after age 50 than brothers who had no "late fertile" sisters. That indicates what earlier studies did not, namely, the same genes may influence the lifespan of both sexes and women's ability to give birth at older ages.


The brothers' wives didn't have longer lives, suggesting any environmental or social factors that influence lifespan had only a weak influence, and that genes may explain why brothers lived longer when they had a sister who gave birth in her 40s.

The study didn't address how much longevity is due to genetics, but Smith says scientists believe genes account for up to 25 percent of differences in longevity.
















Smith conducted the study with two other University of Utah researchers: Richard Cawthon, a research associate professor of human genetics, and demographer Geraldine Mineau, a research professor and director of population sciences at the university's Huntsman Cancer Institute, where Smith also is an investigator. Other coauthors were demographer Alain Gagnon and sociologist Ryan Mazan of the University of Western Ontario, and demographer Bertrand Desjardins, of the University of Montreal.



Good Genes Versus a Good Environment



Smith says that during the last decade, "there have been several studies that show a number of species, including humans, are able to reproduce late without medical intervention - and those females live longer." Other studies found that late menopause also is associated with women having prolonged fertility and longevity.



"There is a genetic component to longevity, especially for living to very old ages," Smith says. "The new thing here is what most evolutionary biologists long have argued: that survival and reproduction are intrinsically linked to one another. So the novel finding in this paper is discovering this link in humans before modern contraception."



But he says the link between late motherhood and longevity "could be something that is not inherited. It could be good nutrition or really good living, suggesting that if you are a healthier mom you live longer."



That is why the researchers looked at the lifespan of the brothers of women who had babies late, and of those brothers' wives. The wives are not blood relatives, so genetic factors shared by sisters and brothers wouldn't be the same in the brothers' wives.



Smith says the study focused on the longevity of brothers rather than sisters of late-fertile women because "men's own reproductive history doesn't get in the way of assessing the role of their female relatives' fertility."



The study focused on the two pioneer groups not only because of the quality of the data but because of the absence of modern birth control and an unfavorable attitude toward natural family planning methods by Mormons and Catholics. Also, a link between late fertility and lifespan is easier to observe in large families with more sisters.



Since all of those studied are now dead, the researchers could look at the full length of their fertile periods and lives. "Not many data sets could do this," Smith says.



The researchers controlled for various factors that could skew the results. For example, they excluded any individuals who did not live to at least 50 because a husband's death at a younger age would influence his wife's child-bearing.



Late Babies Linked to Longer Life for Moms and Blood Uncles
The study confirmed earlier research showing that women who have babies late tend to live longer.



Compared with women who had their last baby before age 41, Utah pioneer women who had their last baby at age 41 to 44 were 6 percent less likely to die during any given year past age 50, and Utah pioneer women who had their final birth at age 45 or older were 14 percent less likely to die during any given year after age 50.



In other words, imagine woman A had her last baby at age 35, woman B had her last baby at 42 and woman C had her last baby at 46. Then at age 52 - or any other age past 50 - woman B would be 6 percent less likely to die than woman A, and woman C would be 14 percent less likely to die than woman A.



In Quebec, slightly different age groups were analyzed. Compared with younger mothers, women who had their last child between ages 42 and 44?? were 6 percent less likely to die during any given year past age 50, and women who had their last child at age 44?? or older were 17 percent less likely to die during any given year past age 50.


By looking at the brothers of women who had children late, the study suggests the same age-slowing genes may be responsible for both prolonged fertility in women and longer lifespan in both sexes. The effects of late fertility were strongest for brothers with at least three sisters because the larger the number of sisters, the more likely it is at least one will give birth in middle age.



So in the Utah group, brothers with three or more sisters - at least one of whom gave birth at age 45 or older - were 20 percent less likely to die during any given year after age 50 than men without late-fertile sisters.



In Quebec, brothers with three or more sisters - at least one of whom gave birth at age 44?? or older - were almost 23 percent less likely to die during any single year after age 50 than men without sisters who gave birth late.


It is possible social and environmental reasons - good water, good nutrition, a healthy environment - could explain why the brothers and their late-birthing sisters had longer lives. So the researchers also examined the longevity of the brothers' wives.

They found no increase in lifespan, indicating that heredity - far more than environmental factors - played a role in the prolonged fertility and longer lives of the women, and the longer lives of their brothers.



Smith says the new findings do not conflict with one of his earlier studies finding that having larger families reduced parents' lifespan. Both findings can operate together.



Source:
Lee Siegel


University of Utah

суббота, 31 декабря 2011 г.

Kaiser Daily Women's Health Policy Report Highlights Recently Released Studies

The following highlights recently released studies on women's health issues.

Pregnancy & Childbirth

"Fostering International Collaboration in Birth Defects Research and Prevention: A Perspective From the International Clearinghouse for Birth Defects Surveillance and Research," American Journal of Public Health: Lorenzo Botto of CDC's National Center on Birth Defects and Developmental Disabilities and colleagues examined three methods of monitoring birth defects: an example of the "intersection of surveillance and research," an example of the "evolution from surveillance to outcome research," and an example of a public health collaboration in genetics (Botto et al., AJPH, 3/29).


"Work Activity in Pregnancy, Preventive Measures, and the Risk of Delivering a Small-for-Gestational-Age Infant," AJPH: Agathe Croteau of the Universite Laval's CHUL Research Centre and colleagues examined women in Quebec who between January 1997 and March 1999 had single live births to evaluate whether "some occupational conditions," such as an irregular daily schedule, during pregnancy increase the likelihood of delivering an infant with a low birthweight. The study concludes, "Certain occupational conditions experienced by pregnant women can increase their risk of having an [infant with a low birthweight], but preventive measures can reduce the risk" (Croteau et al., AJPH, 3/29).


"Factors Associated With the Rise in Primary Cesarean Births in the United States, 1991-2002," AJPH: Eugene Declercq of Boston University's School of Public Health and colleagues from the National Center for Health Statistics examined factors contributing to changes in rates of caesarean sections in the U.S. between 1991 and 2002. The researchers concluded that changes in c-section rates during the study period were not related to shifts in risk profiles of the pregnant women (Declercq et al., AJPH, 3/29).


"Patient Privacy and Conflicting Legal and Ethical Obligations in El Salvador: Reporting of Unlawful Abortions," AJPH: Heathe Luz McNaughton of the University of North Carolina-Chapel Hill School of Public Health and colleagues examined the possible reasons that lead El Salvadorian OB/GYNs to report women who underwent abortion despite "ethical and human rights standards" that "oblige providers to respect patients' privacy" (Luz McNaughton et al., AJPH, 3/29).


"Paternal Age as a Risk Factor for Low Birthweight," AJPH: Nancy Reichman of Robert Wood Johnson Medical School and Julien Teitler of Columbia University evaluated whether there is a connection between paternal age and low birthweight among urban U.S. residents. Reichman and Teitler -- who controlled for maternal age, demographic factors and gender -- concluded that paternal age is a risk factor that contributes to the low birthweight of an infant (Reichman/Teitler, AJPH, 3/29).


"Associations of Maternal Age- and Parity-Related Factors With Trends in Low-Birthweight Rates: United States, 1980 Through 2000," AJPH: Quanhe Yang of CDC and researchers at the University of California-Los Angeles and Emory University's Rollins School of Public Health examined how shifts in the ages of U.S. pregnant women affect birthweight trends. The authors concluded that "delayed childbearing may play an increasingly important role in low-birthweight trends" in the U.S. (Yang et al., AJPH, 4/6).


"Thrombolytic Therapy of Acute Ischemic Stroke During Pregnancy," Neurology: A. Murugappan of the Stroke and Neurological Critical Care Programs at Wayne State University School of Medicine and colleagues examined eight pregnant women whose brains were deprived of oxygen because of a blood clot or other occlusion and who then were treated with thrombolytic therapy to break up the blockage. The study concludes that, while pregnant women can be treated with thrombolytic therapy, "risks and benefits" to both the pregnant woman and the fetus "must be carefully weighed" (Murugappan et al., Neurology, March 2006).

Public Health
"Improving Birth Control Service Utilization By Offering Services Prerelease vs Postincarceration," AJPH: Jennifer Clarke of Rhode Island Hospital and colleagues examined whether providing contraceptive services within a prison compared with after inmates' release would increase female inmates' use of contraceptives. The study finds that providing contraceptives during women's incarceration is "feasible" and "greatly increases birth control initiation" compared with only providing services after their release (Clarke et al., AJPH, 3/29).


"Reproductive Health Care and Family Planning Needs Among Incarcerated Women," AJPH: Clarke and colleagues examined the "level of risk for sexually transmitted diseases ... and the productive health needs" of 484 female inmates in Rhode Island to evaluate how best to plan for their release. The women had "extremely high risks" for sexually transmitted infections and pregnancy because of inconsistent contraceptive and condom use and more than one sexual partners and had a "high prevalence" of unintended pregnancies and STIs, the study finds. The researchers concluded that female inmates need reproductive health services because the services will "benefit the women, the criminal justice systems and the communities to which the women will return" (Clarke et al., AJPH, 3/29).


"Fertility Regulation and Reproductive Health in the Millennium Development Goals: The Search for a Perfect Indicator?" AJPH: Ruth Dixon-Mueller, an independent consultant, and Adrienne Germain of the International Women's Health Coalition examined the U.N. Millennium Development Goals and found that the MDGs are missing a measurement of a woman's ability to "regulate [her] fertility safely and effectively." The study looks at three possible indicators to measure women's reproductive health: "contraceptive prevalence and total fertility; unmet need for contraception and unplanned births; and unsafe abortion and abortion mortality" and recommends that using only one of these measurements is "insufficient." The researchers concluded that a monitoring system should be incorporated into the MDGs or should exist as a "parallel effort by reporting governments and other agencies" (Dixon-Mueller/Germain, AJPH, 3/29).


"Risk for New Onset of Depression During the Menopausal Transition," Archives of General Psychiatry: Lee Cohen of Massachusetts General Hospital and Harvard Medical School and colleagues examined the relationship between menopause and the emergence of depression in women with no history of mood disorders. The study finds that women with no previous diagnosis of depression who experience the menopausal transition earlier have a higher risk of developing depression (Cohen et al., Archives of General Psychiatry, April 2006).


"Associations of Hormones and Menopausal Status With Depressed Mood in Women With No History of Depression," Archives of General Psychiatry: Ellen Freeman, a research professor at the University of Pennsylvania School of Medicine, and colleagues enrolled 231 women who were about to enter menopause and had no history of depression at time of enrollment and studied the women for eight years (Reuters Health, 4/4). The researchers evaluated the women using the Center for Epidemiological Studies of Depression scale and found that women were more than four times as likely to have a score of 16 or greater during the menopausal transition as compared with when they were premenoupausal. In addition, the study finds that women are two-and-a-half times as likely to be diagnosed with a depressive disorder during the menopausal transition compared with when they are premenoupausal (Freeman et al., Archives of General Psychiatry, April 2006).

Sexually Transmitted Infections

"Valacyclovir Therapy To Reduce Recurrent Genital Herpes in Pregnant Women," American Journal of Obstetrics and Gynecology: William Andrews of the Center for Research in Women's Health at the University of Alabama-Birmingham and colleagues examined the effect of Valtrex -- known generically as valacyclovir -- therapy among 112 pregnant women with genital herpes (Williams et al., American Journal of Obstetrics and Gynecology, March 2006). The researchers recorded no symptoms of herpes infection up to two weeks after delivery among any of the infants of the women treated with Valtrex and concluded that Valtrex therapy was safe for both pregnant women and their infants (Douglas, Reuters Health, 4/5).


"Epidemiology of HPV 16 and Cervical Cancer in Finland and the Potential Impact of Vaccination: Mathematical Modelling Analyses," PLoS Medicine: Ruanne Barnabas of the Cancer Epidemiology Unit at the University of Oxford and colleagues developed a transmission model for the most common strain of human papillomavirus -- HPV 16 -- in Finland to estimate the likelihood of virus transmission. Researchers found that HPV vaccines have the potential to reduce the incidence of cervical cancer caused by specific HPV strains. In addition, high levels of vaccine coverage over several decades, along with long-lasting vaccine protection, would have the greatest effect on the incidence of HPV type-specific cervical cancer, the researchers said (Barnabas et al., PLoS Medicine, May 2006).















"Reprinted with permission from kaisernetwork. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at kaisernetwork/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.


View drug information on Valtrex.

суббота, 24 декабря 2011 г.

Senate Panel Holds Hearing On Rape Kit Backlog

A Senate panel on Tuesday held a hearing on the backlog of untested rape kits nationwide, CBS News reports. Several witnesses at the hearing called on lawmakers to address the situation after a CBS investigation revealed 20,000 rape kits in major cities nationwide have never been tested. The investigation also found that an additional 6,000 kits were waiting months or even years to be tested in crime laboratories.

"We need to be figuring a way to get our local law enforcement up to where they need to be," Sen. Jeff Sessions (R-Ala.) said at the hearing.

Several senators called for the bolstering of a 2005 law (P.L. 108-405) designed to reduce the backlog of untested rape kits. According to Linda Fairstein, who led the Manhattan District Attorney's Sex Crimes Unit, New York's effort to test every kit has resulted in a rape arrest rate of 70%. "We need to find, identify, test and get results on every rape kit that exists in this country," she said. Witness Debbie Smith said, "Each box holds within it vital evidence that is crucial to the safety of women everywhere" (Keteyian, CBS News, 12/15).


Reprinted with kind permission from nationalpartnership. You can view the entire Daily Women's Health Policy Report, search the archives, or sign up for email delivery here. The Daily Women's Health Policy Report is a free service of the National Partnership for Women & Families, published by The Advisory Board Company.


© 2009 The Advisory Board Company. All rights reserved.